| Thu, Nov 26, 2009 | | • | CytRx Announces First of Two Positive Developments Ahead
at Seeking Alpha (Thu 5:17am)
| | Tue, Nov 24, 2009 | | • | CytRx Announces Plan to Initiate a Phase 2 Clinical Trial with INNO-206 in Patients with Advanced Soft Tissue Sarcomas
Business Wire (Tue, Nov 24)
| | • | CytRx Corporation: Key Developments Ahead
at Seeking Alpha (Tue, Nov 24)
| | Mon, Nov 23, 2009 | | • | Pending Key Developments Ahead for CytRx Corporation (NASDAQ: CYTR)
Marketwire (Mon, Nov 23)
| | • | CytRx: Technical Breakout Imminent
at Seeking Alpha (Mon, Nov 23)
| | Wed, Nov 18, 2009 | | • | CytRx to Initiate Phase 2 Clinical Trial with INNO-206 in Patients with Advanced Gastric Cancer
Business Wire (Wed, Nov 18)
| | Fri, Nov 13, 2009 | | • | CYTRX CORP Financials
EDGAR Online Financials (Fri, Nov 13)
| | Mon, Nov 9, 2009 | | • | CYTRX CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
EDGAR Online (Mon, Nov 9)
| | • | CYTRX CORP Files SEC form 10-Q, Quarterly Report
EDGAR Online (Mon, Nov 9)
| | • | CytRx Reports 2009 Third Quarter Financial Results
Business Wire (Mon, Nov 9)
| | Wed, Oct 28, 2009 | | • | CytRx Announces Publication of Paper Stating that Chaperone Amplification Represents a 'Significant Strategy' in Anti-aging Pharmaceutical Design
Business Wire (Wed, Oct 28)
| | Thu, Oct 15, 2009 | | • | CYTRX CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
EDGAR Online (Thu, Oct 15)
| | Tue, Oct 13, 2009 | | • | CytRx Fortifies Executive Suite with Addition of Chief Medical Officer
Business Wire (Tue, Oct 13)
| | Mon, Sep 14, 2009 | | • | CytRx and Cephalon Oncology Therapies to be Evaluated as Treatment for Relapsed Acute Promyelocytic Leukemia
Business Wire (Mon, Sep 14)
| | Thu, Sep 10, 2009 | | • | CytRx Secures Key European Patent for Arimoclomol
Business Wire (Thu, Sep 10)
| | Wed, Sep 9, 2009 | | • | Correction: CytRx FDA letter
AP (Wed, Sep 9)
| | • | CytRx to Present at the Sachs Associates Annual Biotech in Europe Investor Forum
Business Wire (Wed, Sep 9)
| | • | CytRx to repsond to FDA letter in 4Q
at bizjournals.com (Wed, Sep 9)
| | Tue, Sep 8, 2009 | | • | CytRx expects to file FDA response in 4Q
AP (Tue, Sep 8)
| | • | CytRx Receives FDA Letter Regarding Arimoclomol Phase IIb Clinical Trial for ALS
Business Wire (Tue, Sep 8)
|
Add CYTR News to My Yahoo!:
 
| |
|
1.33% Nasdaq 
0.0099 (0.94%) 
Headlines
